What is AI Proteins?
Founded in 2021, AI Proteins operates at the intersection of artificial intelligence and structural biology. The company specializes in the de novo design of synthetic proteins, a process that bypasses traditional evolutionary constraints to create novel molecules with specific, optimized functions. By utilizing high-throughput computational modeling, AI Proteins aims to address complex biological challenges that have historically been considered undruggable. Their market position is defined by a unique ability to rapidly iterate and validate protein structures, providing a scalable solution for pharmaceutical partners and internal drug discovery pipelines. As the biotech industry shifts toward AI-driven research, AI Proteins stands out as a critical infrastructure player capable of accelerating the timeline from target identification to clinical candidate selection.
How much funding has AI Proteins raised?
AI Proteins has raised a total of $59.7M across 2 funding rounds:
Angel/Seed
$18.2M
Series A
$41.5M
Angel/Seed (2022): $18.2M with participation from Lightchain Capital and Cobro Ventures
Series A (2025): $41.5M led by Lightchain Capital, Mission BioCapital, Santé Ventures, and Cobro Ventures
Key Investors in AI Proteins
Lightchain Capital
Lightchain Capital is a venture capital fund that specializes in investing in early-stage life sciences companies. The firm is dedicated to supporting innovations aimed at improving patient outcomes in cancer treatment.
Mission BioCapital
Mission BioCapital is a venture capital firm that provides early-stage capital to innovative life science entrepreneurs. Their approach emphasizes creativity and respect for founders, aiming to revolutionize the journey from discovery to medical breakthroughs.
Santé Ventures
Santé is a privately held investment firm that focuses on innovative healthcare and technology companies. They seek visionary entrepreneurs and ideas that can enhance patient health outcomes through advanced data science and machine learning.
What's next for AI Proteins?
With this major enterprise-level funding, AI Proteins is well-positioned to scale its computational infrastructure and expand its laboratory capabilities. The strategic roadmap likely includes the acceleration of its internal pipeline of synthetic protein therapeutics and the potential for high-value partnerships with global pharmaceutical entities. By deepening its investment in talent and proprietary software, the company aims to solidify its competitive moat in the rapidly evolving synthetic biology landscape. Future growth will be measured by the successful transition of its de novo designs into preclinical and clinical development, further validating the efficacy of its AI-first approach to protein engineering.
See full AI Proteins company page
